Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event Psychedelics Investing
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights Psychedelics Investing
Hollister Biosciences Inc. Launches Rebrand to Yourway Cannabis Brands Inc. and Bold New Strategy Psychedelics Investing
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors Psychedelics Investing
Lobe Sciences Announces That Its Shares Will Trade on the OTCQB Market in the United States Pharmaceutical Investing
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study Psychedelics Investing
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
